Strategies of temozolomide in future glioblastoma treatment

Research output: Contribution to journalReview ArticleResearchpeer-review

66 Citations (Scopus)

Abstract

Glioblastoma multiforme (GBM) may be one of the most challenging brain tumors to treat, as patients generally do not live more than 2 years. This review aimed to give a timely review of potential future treatments for GBM by looking at the latest strategies, involving mainly the use of temozolomide (TMZ). Although these studies were carried out either in vitro or in rodents, the findings collectively suggested that we are moving toward developing a more efficacious therapy for GBM patients. Nanoparticles preparation was, by far, the most extensively studied strategy for targeted brain delivery. Therefore, the first section of this review presents a treatment strategy using TMZ-loaded nanocarriers, which encompassed nanoparticles, nanoliposomes, and nanosponges. Besides nanocarriers, new complexes that were formed between TMZ and another chemical agent or molecule have shown increased cytotoxicity and antitumor activity. Another approach was by reducing GBM cell resistance to TMZ, and this was achieved either through the suppression of metabolic change occurring in the cells, inhibition of the DNA repair protein, or up-regulation of the protein that mediates autophagy. Finally, the review collates a list of substances that have demonstrated the ability to suppress tumor cell growth.

Original languageEnglish
Pages (from-to)265-270
Number of pages6
JournalOncoTargets and Therapy
Volume10
DOIs
Publication statusPublished - 9 Jan 2017

Keywords

  • Cellular resistance
  • Glioblastoma multiforme
  • Nanoparticles
  • Targeted delivery
  • Temozolomide

Cite this